Analyst Research
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$58.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Given Imaging Ltd Halts Sale Review, Investor May Sell Stake-Reuters
Reuters reported that Given Imaging is no longer considering a sale or merger and will instead focus on its existing operating plan, as well as potential acquisitions and alliances, the camera-in-a-pill maker said. The Israeli medical devices maker also said 45.5% shareholder Discount Investment Corp planned to seek and consider a sale of its stake in one block. There can be no assurance that any transaction will occur, Given Imaging added. Terms of the transaction were not disclosed.
Latest Developments for Given Imaging Ltd
- Given Imaging Ltd Announces New Data Highlighting PillCam COLON Comparability To Colonoscopy In Detecting Adenomas
- Given Imaging Ltd Reaffirms FY 2013 Guidance
- Given Imaging Ltd Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates; EPS Guidance Above Analysts' Estimates
- Given Imaging Ltd Submits PillCam COLON 2 Application to FDA for U.S. Regulatory Clearance
- Share this
- Link this
- Digg this


Follow Reuters